These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 23002203)

  • 101. Role of ABL family kinases in cancer: from leukaemia to solid tumours.
    Greuber EK; Smith-Pearson P; Wang J; Pendergast AM
    Nat Rev Cancer; 2013 Aug; 13(8):559-71. PubMed ID: 23842646
    [TBL] [Abstract][Full Text] [Related]  

  • 102. Current Progress on the Influence Human Genetics Has on the Efficacy of Tyrosine Kinase Inhibitors Used to Treat Chronic Myeloid Leukemia.
    Prakash TC; Enkemann S
    Cureus; 2024 Mar; 16(3):e56545. PubMed ID: 38646295
    [TBL] [Abstract][Full Text] [Related]  

  • 103. The molecular basis of Abelson kinase regulation by its αI-helix.
    Paladini J; Maier A; Habazettl JM; Hertel I; Sonti R; Grzesiek S
    Elife; 2024 Apr; 12():. PubMed ID: 38588001
    [TBL] [Abstract][Full Text] [Related]  

  • 104. Imatinib disassembles the regulatory core of Abelson kinase by binding to its ATP site and not by binding to its myristoyl pocket.
    Grzesiek S; Paladini J; Habazettl J; Sonti R
    Magn Reson (Gott); 2022; 3(1):91-99. PubMed ID: 37905178
    [TBL] [Abstract][Full Text] [Related]  

  • 105. Patient-Specific Pharmacokinetics and Dasatinib Nephrotoxicity.
    Adegbite BO; Abramson MH; Gutgarts V; Musteata FM; Chauhan K; Muwonge AN; Meliambro KA; Salvatore SP; El Ghaity-Beckley S; Kremyanskaya M; Marcellino B; Mascarenhas JO; Campbell KN; Chan L; Coca SG; Berman EM; Jaimes EA; Azeloglu EU
    Clin J Am Soc Nephrol; 2023 Sep; 18(9):1175-1185. PubMed ID: 37382967
    [TBL] [Abstract][Full Text] [Related]  

  • 106. Unbiased evaluation of rapamycin's specificity as an mTOR inhibitor.
    Artoni F; Grützmacher N; Demetriades C
    Aging Cell; 2023 Aug; 22(8):e13888. PubMed ID: 37222020
    [TBL] [Abstract][Full Text] [Related]  

  • 107. Targeting the PTP1B-Bcr-Abl1 interaction for the degradation of T315I mutant Bcr-Abl1 in chronic myeloid leukemia.
    Elgehama A; Wang Y; Yu Y; Zhou L; Chen Z; Wang L; Sun L; Gao J; Yu B; Shen Y; Xu Q
    Cancer Sci; 2023 Jan; 114(1):247-258. PubMed ID: 36086954
    [TBL] [Abstract][Full Text] [Related]  

  • 108. Allosteric regulation of autoinhibition and activation of c-Abl.
    Liu Y; Zhang M; Tsai CJ; Jang H; Nussinov R
    Comput Struct Biotechnol J; 2022; 20():4257-4270. PubMed ID: 36051879
    [TBL] [Abstract][Full Text] [Related]  

  • 109. Oncogenic Signalling of PEAK2 Pseudokinase in Colon Cancer.
    Lecointre C; Fourgous E; Montarras I; Kerneur C; Simon V; Boublik Y; Bonenfant D; Robert B; Martineau P; Roche S
    Cancers (Basel); 2022 Jun; 14(12):. PubMed ID: 35740644
    [TBL] [Abstract][Full Text] [Related]  

  • 110. Asciminib and ponatinib exert synergistic anti-neoplastic effects on CML cells expressing
    Gleixner KV; Filik Y; Berger D; Schewzik C; Stefanzl G; Sadovnik I; Degenfeld-Schonburg L; Eisenwort G; Schneeweiss-Gleixner M; Byrgazov K; Sperr WR; Mayer J; Lion T; Valent P
    Am J Cancer Res; 2021; 11(9):4470-4484. PubMed ID: 34659899
    [TBL] [Abstract][Full Text] [Related]  

  • 111. A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs.
    Réa D; Mauro MJ; Boquimpani C; Minami Y; Lomaia E; Voloshin S; Turkina A; Kim DW; Apperley JF; Abdo A; Fogliatto LM; Kim DDH; le Coutre P; Saussele S; Annunziata M; Hughes TP; Chaudhri N; Sasaki K; Chee L; García-Gutiérrez V; Cortes JE; Aimone P; Allepuz A; Quenet S; Bédoucha V; Hochhaus A
    Blood; 2021 Nov; 138(21):2031-2041. PubMed ID: 34407542
    [TBL] [Abstract][Full Text] [Related]  

  • 112. Small molecules in targeted cancer therapy: advances, challenges, and future perspectives.
    Zhong L; Li Y; Xiong L; Wang W; Wu M; Yuan T; Yang W; Tian C; Miao Z; Wang T; Yang S
    Signal Transduct Target Ther; 2021 May; 6(1):201. PubMed ID: 34054126
    [TBL] [Abstract][Full Text] [Related]  

  • 113. Bcr-Abl Allosteric Inhibitors: Where We Are and Where We Are Going to.
    Carofiglio F; Trisciuzzi D; Gambacorta N; Leonetti F; Stefanachi A; Nicolotti O
    Molecules; 2020 Sep; 25(18):. PubMed ID: 32937901
    [TBL] [Abstract][Full Text] [Related]  

  • 114. Cardiotoxicity of the BCR-ABL1 tyrosine kinase inhibitors: Emphasis on ponatinib.
    Singh AP; Umbarkar P; Tousif S; Lal H
    Int J Cardiol; 2020 Oct; 316():214-221. PubMed ID: 32470534
    [TBL] [Abstract][Full Text] [Related]  

  • 115. Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants.
    Eide CA; Zabriskie MS; Savage Stevens SL; Antelope O; Vellore NA; Than H; Schultz AR; Clair P; Bowler AD; Pomicter AD; Yan D; Senina AV; Qiang W; Kelley TW; Szankasi P; Heinrich MC; Tyner JW; Rea D; Cayuela JM; Kim DW; Tognon CE; O'Hare T; Druker BJ; Deininger MW
    Cancer Cell; 2019 Oct; 36(4):431-443.e5. PubMed ID: 31543464
    [TBL] [Abstract][Full Text] [Related]  

  • 116. The phosphatase UBASH3B/Sts-1 is a negative regulator of Bcr-Abl kinase activity and leukemogenesis.
    Mian AA; Baumann I; Liebermann M; Grebien F; Superti-Furga G; Ruthardt M; Ottmann OG; Hantschel O
    Leukemia; 2019 Sep; 33(9):2319-2323. PubMed ID: 30962580
    [No Abstract]   [Full Text] [Related]  

  • 117. Ponatinib-induced cardiotoxicity: delineating the signalling mechanisms and potential rescue strategies.
    Singh AP; Glennon MS; Umbarkar P; Gupte M; Galindo CL; Zhang Q; Force T; Becker JR; Lal H
    Cardiovasc Res; 2019 Apr; 115(5):966-977. PubMed ID: 30629146
    [TBL] [Abstract][Full Text] [Related]  

  • 118. Molecular biology as a tool for the treatment of cancer.
    de Castro Sant' Anna C; Junior AGF; Soares P; Tuji F; Paschoal E; Chaves LC; Burbano RR
    Clin Exp Med; 2018 Nov; 18(4):457-464. PubMed ID: 30006681
    [TBL] [Abstract][Full Text] [Related]  

  • 119. Chronic myeloid leukemia patients and treatment-free remission attitudes: a multicenter survey.
    Lou J; Huang J; Wang Z; Wen B; Tu C; Huang W; Zhai Z; Du X
    Patient Prefer Adherence; 2018; 12():1025-1032. PubMed ID: 29942119
    [TBL] [Abstract][Full Text] [Related]  

  • 120. Structural and functional dissection of the DH and PH domains of oncogenic Bcr-Abl tyrosine kinase.
    Reckel S; Gehin C; Tardivon D; Georgeon S; Kükenshöner T; Löhr F; Koide A; Buchner L; Panjkovich A; Reynaud A; Pinho S; Gerig B; Svergun D; Pojer F; Güntert P; Dötsch V; Koide S; Gavin AC; Hantschel O
    Nat Commun; 2017 Dec; 8(1):2101. PubMed ID: 29235475
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.